Erasca (ERAS) has skyrocketed 460% in the past year, hitting a new 3-year high of $10.92. Despite bullish technicals, ERAS has no revenue, burning cash. Analysts have speculative price targets ranging from $2 to $16, with a market cap of $3.25 billion.

With a Weighted Alpha of +409.79, ERAS has a 100% “Buy” opinion from Barchart and a Trend Seeker “Buy” signal intact. The stock is up 460.32% in the past 52 weeks, with 13 new highs and a 50-day moving average of $5.34. RSI is at 79.10, with technical support around $10.24.

Analysts give ERAS 8 “Strong Buy,” 2 “Hold,” and 1 “Moderate Sell” rating, with price targets from $2 to $16. Value Line rates it “Average,” CFRA’s MarketScope rates it “Hold,” and Morningstar thinks it’s undervalued by 13%. Short interest is 7.22% with 7.72 days to cover.

ERAS, a clinical-stage oncology company, has no revenue but enough cash to sustain operations through 2028. Analysts and investors are optimistic, but revenue and earnings depend on FDA drug approvals. Speculative stock with high volatility, proceed with caution.

Read more at Yahoo Finance: Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock?